Today: 13 May 2026
Oracle’s ‘Truly Awesome’ AI Cloud Quarter Sends Stock Soaring 36%, Making Ellison World’s Richest
17 November 2025
3 mins read

Oracle Stock Today (Nov 17, 2025): ORCL Slips as Credit Hedges Rise; Jefferies Reaffirms $400 Target and 80% Upside

Published: November 17, 2025

Key takeaways

  • Price action: Oracle (NYSE: ORCL) traded near $220 in midday U.S. trading, down roughly 1% from Friday’s close, with an intraday range around $217–$225.
  • Fresh analyst call:Jefferies’ Brent Thill reiterated a Buy and $400 price target—implying about 80% upside—arguing debt and customer concentration fears are overdone.
  • Credit-market signal:Reuters reports Saba Capital sold credit default swaps (CDS) referencing Oracle and other Big Tech names, as lenders hedge risks tied to AI-fueled borrowing.
  • Bond backdrop (today):Axios highlights Oracle’s 30‑year bond dropping about 8% since October and trading near 65 cents on the dollar, underscoring investor caution on AI capex.
  • Near-term calendar: Oracle’s 2025 Annual Meeting of Stockholders is tomorrow, Nov. 18; next earnings are mid‑December (Q2 FY2026), per Investor Relations.

What moved Oracle stock today

Jefferies sticks with $400 target, sees selloff as overdone.
In a note published this morning, Jefferies’ Brent Thill reaffirmed a $400 target on Oracle, framing the recent drawdown as an opportunity. The call cites a still‑large non‑OpenAI backlog and argues Oracle’s capex approach limits upfront cash strain versus owning all the infrastructure outright.

Hedging picks up in credit markets—Oracle included.
An exclusive from Reuters says Saba Capital has been selling CDS protection on Oracle, Microsoft, Meta, Amazon, and Alphabet to banks seeking to hedge exposure to the sector’s accelerating, debt‑financed AI build‑out. The story notes Oracle’s five‑year CDS recently climbed to multi‑year highs, a sign of rising perceived credit risk (still modest versus many other sectors).

Oracle’s bond slump remains in focus.
A same‑day Axios piece underscores the pressure on Oracle’s long‑dated paper, with the company’s $3.5B 30‑year issue down about 8% since October and quoted near 65 cents on the dollar. The article ties the move to broader investor unease about the cost and pace of AI infrastructure spending across Big Tech.


Price action: where ORCL stood intraday

By early afternoon in New York, ORCL hovered around $221 with session lows near $217 and highs near $225, putting shares modestly lower versus Friday’s close. Volatility reflects dueling narratives: a bullish sell‑side view on multi‑year AI cloud demand versus growing credit‑market caution around the financing required to deliver it.


How today’s headlines fit the bigger picture

Debt, data centers, and the “AI capex” narrative.
Oracle’s bonds sold off late last week after reports it may seek ~$38B in additional financing to expand AI infrastructure, building on $18B raised in September. That pressure spilled into this week’s commentary as investors reassess leverage and payback periods for AI investments. Reuters+1

Project‑finance pipeline and the Stargate build‑out.
Separately, Bloomberg‑reported (via Reuters) $18B in project‑finance loans linked to an Oracle‑tied data‑center campus in New Mexico remains a notable data point: it illustrates how capital for AI infrastructure is being syndicated beyond bond markets into large, multi‑lender facilities.

Risk checks remain on the radar.
Investors are still digesting Moody’s September note flagging concentration risks in Oracle’s recently announced AI contracts—context for why today’s CDS and bond‑market moves matter for the equity story.


Analyst angle—what the Street is emphasizing today

  • Jefferies (today): Maintains Buy/$400, arguing concentration and debt concerns are “overblown,” with non‑OpenAI commitments still large and growing. MarketWatch
  • Market context: Even as spreads widen for AI‑exposed issuers, today’s Reuters piece suggests current CDS levels for megacap tech remain well inside broader investment‑grade stress—important nuance for assessing tail risk.

What to watch next

  • Annual Meeting (tomorrow): Oracle’s virtual annual meeting is set for Nov. 18, 9:00 a.m. CT, which could surface shareholder questions around funding strategy, timing of new capacity, and governance.
  • Earnings (mid‑December): Management commentary on Q2 FY2026—particularly OCI capacity additions, contract conversion to revenue, and any financing updates—will be pivotal into year‑end.
  • Credit market tone: Watch whether CDS and long‑dated bond pricing stabilize; sentiment here has been a leading indicator for AI‑capex‑heavy names lately.

Bottom line

For Nov. 17, 2025, Oracle stock is soft but orderly as investors balance bullish AI demand narratives against financing and execution risk that’s now showing up more clearly in the bond and CDS markets. The Jefferies note keeps a robust upside case alive on backlog and capital efficiency, but the cost of capital—and how Oracle sequences its build—remains the swing factor into the annual meeting and December earnings.


This article is for information only and is not investment advice.

Stock Market Today

  • Anthropic Warns Against Tokenized Pre-IPO Shares Amid Price Turmoil
    May 13, 2026, 1:21 PM EDT. Anthropic, creator of AI model Claude, has declared tokenized products claiming access to its private shares are invalid. The company labeled unauthorized transfers through tokenized securities, forward contracts, or special purpose vehicles (SPVs) as "void," highlighting risks in crypto pre-IPO markets. Following the warning, PreStocks' tokenized Anthropic shares plunged nearly 50%, though other tokenized exposure forms showed less volatility. This follows a broader trend where several platforms offer pseudo exposure to high-profile private companies like OpenAI and SpaceX, despite transfer restrictions and regulatory concerns. Anthropic's firm stance underscores significant legal and structural risks linked to tokenized private equity instruments.

Latest articles

Ondas Stock on Watch After SkyLance Test and Mistral Share Filing Before Q1 Earnings

Ondas Stock on Watch After SkyLance Test and Mistral Share Filing Before Q1 Earnings

13 May 2026
Ondas Inc.’s Rotron Aerospace completed a firing demo of its SkyLance long-range one-way effector ahead of Ondas’s Q1 results release. Ondas shares fell 12 cents to $8.92 after the company filed for resale of 2.77 million shares tied to its $175 million Mistral acquisition. The Mistral deal boosted Ondas’s backlog to $457 million as of March 31. Rotron was acquired in March for $6.7 million cash and 3.33 million shares.
Gold Price Drop Deepens as Hot Inflation Shakes Fed Bets Before Trump-Xi Talks

Gold Price Drop Deepens as Hot Inflation Shakes Fed Bets Before Trump-Xi Talks

13 May 2026
Spot gold fell 0.6% to $4,686.99 an ounce Wednesday after U.S. inflation data fueled bets on higher-for-longer interest rates, pressuring bullion. U.S. gold futures edged up 0.2%. India raised gold and silver import tariffs to 15%, sending local gold futures up 7.2%. Treasury yields climbed toward their highest since July, adding further drag for gold.
UiPath Stock Drops as Its AI Agent Bet Hits a Hard Earnings Test

UiPath Stock Drops as Its AI Agent Bet Hits a Hard Earnings Test

13 May 2026
UiPath Inc. shares dropped 5.9% to $9.42 on Wednesday, with trading volume above 22 million, after the company launched a new integration for AI coding agents but investors waited for clearer demand signals ahead of its May 28 earnings call. UiPath reported fourth-quarter revenue of $481 million, up 14%, and reached full-year GAAP profitability for the first time.

Popular

Stock Market Today: Dow Drops as Hot Inflation Data Puts Fed Rate Cuts on Ice

Stock Market Today: Dow Drops as Hot Inflation Data Puts Fed Rate Cuts on Ice

13 May 2026
The U.S. producer price index jumped 1.4% in April, its largest monthly rise since March 2022, pushing the S&P 500 down 0.10% and the Dow off 0.35% late Wednesday morning. The Nasdaq edged up 0.07% as chip stocks rebounded, with the Philadelphia semiconductor index gaining 1.7%. Traders increased bets on no Fed rate cuts this year after the inflation data.
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover
Previous Story

Novo Nordisk Slashes Wegovy and Ozempic Cash Prices to $349, Launches $199 Intro Deals as GLP‑1 Price War Escalates

Cisco’s $2B AI Windfall: New Tech, Stock Surge & What’s Next for CSCO
Next Story

Cisco (CSCO) Stock Today, November 17, 2025: AI Orders, EzDubs Deal and New Analyst Upgrades Fuel Momentum

Go toTop